Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 4 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Endobronchial Metastases 1Emergence Delirium 1Delirium 1

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 32Bupivacaine 31Vincristine 27Cisplatin 26Propofol 25Methotrexate 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Bevacizumab 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Ropivacaine 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × OTHER × remimazolam × Clear all
NCT04532606 2025-07-30

Impact of Remimazolam on Prognosis After Bladder Cancer Surgery

Peking University First Hospital

Phase 4 Recruiting
1,128 enrolled
Genitourinary

Emergence Delirium, Urinary Bladder Neoplasms, Delirium

NCT05468671 2022-10-26

Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy

Zhejiang Cancer Hospital

Phase 4 Completed
34 enrolled
GastrointestinalThoracic

Endobronchial Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡